Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2005

View Archived Issues

Anti-Alzheimer's effect of statins may be mediated via antiinflammatory effects on microglia

European approval for NovoMix 50 and NovoMix 70 insulin analogues

GenPat77 receives grant to advance CEACAM1 into clinical testing

Phase III Photrex study for wet AMD begins enrollment

Treatment completed in phase I/II study of GTP-200 for cancer cachexia

Medtronic submits first PMA module for Endeavor stent

Eisai and TorreyPines sign new Alzheimer's research agreement

Myriad Genetics plans preclinical data submission for antithrombin drug

Phase II trial begins for CDA-1 for C. difficile-associated diarrhea

Treatment completed in phase II/III trial of Diamyd

VIRxSYS completes financing

Phase III Evamist study completes enrollment

Chugai patent describes new vitamin D receptor agonists for urological disorders

Novel agents for treating endocrine-related disorders disclosed in recent patents

HCV protease inhibitors claimed in recent Vertex patent

Recent Lilly and Bayer patents report novel agents for obesity and lipoprotein disorders

5-HT3 receptor antagonists suppress beta-amyloid-induced neurotoxicity

Preclinical data on peptide YY3-36

Rho kinase inhibitor improves responses of the cavernosal smooth muscle in rats

A-317567 -- First blocker of ASICs implicated in pain pathways

Update on the cardiac benefits of istaroxime

Seibule approved in Japan for postprandial hyperglycemia

Topical tacrolimus reported effective in children with atopic dermatitis

Gemifloxacin shows efficacy in acute bacterial sinusitis and AECB

Japan approves fluvoxamine maleate for social anxiety disorder

Ebixa receives European approval for moderate Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...